X4 Pharmaceuticals: Betting On Mavorixafor For Chronic Neutropenia (NASDAQ:XFOR)

Core Insights - X4 Pharmaceuticals, Inc. is a biopharmaceutical company focused on its primary asset, Mavorixafor, which is commercially branded as Xolremdi and approved in the US for WHIM syndrome [1] Company Overview - The company is in the process of expanding the use of Mavorixafor beyond its current approval for WHIM syndrome [1]